Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$3.81
+1.5%
$2.66
$1.89
$4.09
$1.13B0.623.42 million shs1.95 million shs
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$23.18
-1.7%
$24.73
$22.64
$53.96
$1.09B0.72495,165 shs221,782 shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$9.05
+1.2%
$11.69
$6.36
$47.45
$995.72M1.081.82 million shs1.99 million shs
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$5.22
+2.6%
$5.92
$1.16
$10.37
$278.43M0.33422,842 shs147,080 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
0.00%+5.40%+60.55%+82.06%+40.41%
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.00%+0.41%-9.19%-12.91%-39.90%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.00%-5.43%-35.31%+9.30%-73.45%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
0.00%+2.15%-9.53%+11.54%+331.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.4514 of 5 stars
3.41.00.00.03.23.30.0
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
4.3633 of 5 stars
3.12.00.03.71.94.21.3
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3.7768 of 5 stars
4.53.00.00.02.93.30.0
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
3.0699 of 5 stars
3.53.00.00.03.41.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.75
Moderate Buy$8.33119.01% Upside
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
2.25
Hold$32.3339.52% Upside
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3.00
Buy$41.13354.42% Upside
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
3.00
Buy$8.5062.84% Upside

Current Analyst Ratings Breakdown

Latest TKNO, AMPH, DYN, and ABCL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/25/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/24/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$13.00
6/18/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
6/18/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$46.00 ➝ $32.00
6/17/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
6/11/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$37.00
6/2/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$60.00 ➝ $34.00
5/29/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$46.00
5/16/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $10.00
5/12/2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral$45.00 ➝ $30.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$28.83M39.39N/AN/A$3.58 per share1.06
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$731.97M1.49$4.99 per share4.64$15.23 per share1.52
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$6.19 per shareN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$37.74M7.39N/AN/A$1.55 per share3.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$162.86M-$0.56N/AN/AN/A-737.56%-15.98%-12.38%8/5/2025 (Estimated)
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$159.52M$2.768.407.046.0419.38%22.20%10.40%8/6/2025 (Estimated)
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$317.42M-$3.59N/AN/AN/AN/A-52.83%-48.84%8/11/2025 (Estimated)
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$26.75M-$0.48N/AN/AN/A-60.90%-28.48%-19.73%8/12/2025 (Estimated)

Latest TKNO, AMPH, DYN, and ABCL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million
5/8/2025Q1 2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.88-$1.05-$0.17-$1.05N/AN/A
5/8/2025Q1 2025
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$0.11-$0.09+$0.02-$0.09$9.41 million$9.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
N/AN/AN/AN/AN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
10.15
10.15
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.80
2.95
2.02
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/A
20.35
20.35
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
0.17
5.64
4.71

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
65.09%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
13.81%

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.90%
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
27.10%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
20.77%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
12.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
500298.42 million212.18 millionOptionable
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
2,02847.14 million34.36 millionOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
100113.67 million90.06 millionOptionable
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
24053.44 million46.76 millionNot Optionable

Recent News About These Companies

Alpha Teknova, Inc. (TKNO) Income Statement - Yahoo Finance
Teknova Reports First Quarter 2025 Financial Results
BTIG Reaffirms Their Hold Rating on Alpha Teknova (TKNO)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$3.80 +0.06 (+1.47%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$3.78 -0.02 (-0.53%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Amphastar Pharmaceuticals stock logo

Amphastar Pharmaceuticals NASDAQ:AMPH

$23.18 -0.41 (-1.72%)
Closing price 07/3/2025 03:50 PM Eastern
Extended Trading
$23.18 0.00 (0.00%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$9.05 +0.11 (+1.23%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$8.99 -0.06 (-0.62%)
As of 07/3/2025 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Alpha Teknova stock logo

Alpha Teknova NASDAQ:TKNO

$5.22 +0.13 (+2.55%)
As of 07/3/2025 01:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.